Following a review of its strategic options, Swedish immunology company InDex Pharmaceuticals has opted for a reverse merger with Stockholm-based Flerie Invest. 21 May 2024
Australian radiopharma developer Telix Pharmaceuticals has filed for a secondary listing, with proposals for an initial public offering in the USA. 20 May 2024
Precision oncology company Erasca, which is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, 17 May 2024
In an Expert View column.Bruce Leuchter.chief executive of Neurvati Neurosciences.a Blackstone Life Sciences portfolio company.outlines the importance of increa 17 May 2024
USA and UK-based cancer cell therapy developer Adaptimmune Therapeutics has secured $125 million in financing, with the first tranche of $25 million available u 16 May 2024
At a cool $1 billion, the venture round secured by AI group Xaira ranks as the second-biggest raise in biotech history. In the drug discovery space, this financ 14 May 2024
Immuno-oncology company iTeos Therapeutics has lofty ambitions, claiming to be pioneering the discovery and development of a new generation of highly differenti 13 May 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.